The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

January is Mental Wellness Month! We asked Heather Rose Artushin, a licensed clinical social worker, to share information and insights into understanding and protecting your mental health when you ...

In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

The Lupus Foundation of America uses an electronic grant submission process. All applicants must submit their full application packages through the ProposalCentral online grants management system.

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...